Page 37 - 84_02

59. Hall JM, Lee MK, Newman B, Morrow JE, Anderson
LA, Huey B, King MC. Linkage of early-onset
familial breast cancer to chromosome 17q21. Science
1990; 250: 1684-9.
60. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, et
al. A strong candidate for the breast and ovarian
cancer susceptibility gene BRCA1. Science 1994;
266: 66-71.
61. Sekar A, Bialas AR, de Rivera H, Davis A, et al.
Schizophrenia risk from complex variation of
complement component 4. Nature 2016; 530: 177-83.
62. Handyside AH, Kontogianni EH, Hardy K, Winston
RM. Pregnancies from biopsied human
preimplantation embryos sexed by Y-specific DNA
amplifications. Nature 1990; 344: 25-6.
63. Jaenich R, MintzB. Simian virus 40 DNA squences in
DNA of healthy adult mice derived from
primplantation blastocytes inyected with viral DNA.
Proc Natl Acad Sci USA 1974; 71: 1.250-4.
64. Thomas KR, Capecchi RM. Site-directed mutagenesis
by gene targeting in mouse embryo-derived stem cells.
Cell 1987; 51: 503-12.
65. a) Wivel NA, Anderson WF. Human gene therapy.
Public policy and regulatory issues. Cold Spring
Harbor Monograph Archive 1999; Chapter 24, nº 36:
671-89. b) Anderson WF. The best of times, the worst
of times. Science 2000; 288: 627.
66. Booth C, Gaspar HB. Pegademase bovine (PEG-ADA)
for the treatment of infants and children with severe
combined immunodeficiency (SCID). Biologics:
Targets and Therapy 2009; 3: 349-58.
67. Lehrmas S. Virus treatment questioned after gene
therapy death. Nature 1999; 401: 517-8.
68. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C,
et al. Long term safety and efficacy of factor IX gene
therapy in hemophilia B. New England Journal of
Medicine 2014; 371; 1.994-2.004.
69. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz
MA, et al. Embryonic stem cell lines derived from
human blastocysts. Science 1998; 282: 1145-7.
70. Wertz DW. Embryo and stem cell research in the
United States. History and politics. Gene Therapy
2002; 9: 674-8.
71. Tang WW, Dietmann S, Irie N, Leitch HG, et al. A
Unique Gene Regulatory Network Resets the Human
Germline Epigenome for Development. Cell
2015;161: 1.453-67.
72. Avendaño C, Menéndez JC. “Gene therapy” en
“Medicinal Chemistry of Anticancer Drugs”, 2015,
Ed. Elsevier, pág. 582 y siguientes.
73. Ferguson MS, Lemoine NR, Wang Y. Systemic
Delivery of Oncolytic Viruses: Hopes and Hurdles.
Adv Virol 2012; 2012: 1-14.
74. Pan J-J, Zhang SW, Chen C-B, Xiao S-W, et al. Effect
of recombinant adenovirus-p53 combined with
radiotherapy on long-term prognosis of advanced
152
M.ª del Carmen Avendaño López
nasopharyngeal carcinoma. J Clin Oncol 2009; 27:
799-804.
75. Andtbacka RH, Kaufman HL, Collichio F, Amatruda
T, et al. Talimogene Laherparepvec Improves Durable
Response Rate in Patients With Advanced Melanoma.
J Clin Oncol 2015; 33: 2780-8.
76. Sandmair AM, Loimas S, Puranen P, Immonen A, et
al. Thymidine kinase gene therapy for human
malignant glioma, using replication-deficient
retroviruses or adenoviruses. Hum Gene Ther 2000;
11: 2197-205.
77. Jin Z, Maiti S, Huls H, Sing H, Olivares S, et al. The
hyperactive Sleeping Beauty transposase SB100X
improves the genetic modification of T cells to
express a chimeric antigen receptor. Gene Ther 2011;
18: 849-56.
78. Madan RA, Arlen PM, Mohebtash M, Hodge JW, et al.
Prostvac-VF: a vector-based vaccine targeting PSA in
prostate cancer. Expert Opin Invest Drugs 2009; 18:
1001-11.
79. Khuri FR, Kurie JM. Antisense approaches enter the
clinic. Clin Cancer Res 2000; 6: 1607-13.
80. Moreno PM, Pego AP. Therapeutic antisense
oligonucleotides against cancer: hurdling to the clinic.
Front Chem 2014; 2: 87.
81. Barrangou R, Fremaux C, Deveau H, Richards M, et
al. CRISPR provides acquired resistance against
viruses in prokaryotes. Science 2007; 23; 315: 1709-
12.
82. a) Mojica FJ, Juez G, Rodríguez-Valera F.
Transcription at different salinities of Haloferax
mediterranei sequences adjacent to partially modified
PstI sites. Mol Microbiol 1993; 9: 613-21. b) Mojica
FJ, Díez-Villaseñor C, García-Martínez J, Soria E.
Intervening sequences of regularly spaced prokaryotic
repeats derive from foreign genetic elements. J Mol
Evol. 2005; 60:174-82.
83. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA,
Charpentier E. A programmable dual-RNA-guided
DNA endonuclease in adaptive bacteral immunity.
Science 2012; 337: 816-21.
84. Gasiunas G, Barrangou R, Horvath Ph, Siksnys V.
Cas9–crRNA ribonucleoprotein complex mediates
specific DNA cleavage for adaptive immunity in
bacteria. PNAS 2012 ; 109: 15539-40.
85. Sander JD, Joung JK. CRISPR-Cas systems for
editing, regulating and targeting genomes. Nature
Biotechnology 2014; 32: 347-55.
86. Nakade S, Tsubota T, Sakane Y, Kume S, et al.
Microhomology-mediated end-joining-dependent
integration of donor DNA in cells and animals using
TALENs and CRISPR/Cas9. Nature Communications
2014; 5: 5560.
87. McCarthy J. 10 ways CRISPR (gene-editing) can fight
poverty. Global Citizen, 27 Nov. 2015.
@Real Academia Nacional de Farmacia. Spain